Segments (Tables)

6 Months Ended

Jun. 30, 2022

Segment Adjusted EBITDA by reportable segment was as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Biopharmaceuticals	$	(11,249)	$	(12,540)	$	(22,869)	$	(21,394)
Exemplar	795		1,889		4,353		3,695

Segment Adjusted EBITDA for reportable segments	$	(10,454)	$	(10,651)	$	(18,516)	$	(17,699)

Revenues by reportable segment were as follows:


	Three Months Ended June 30, 2022
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	70	$	2,841	$	2,911
Intersegment revenues	—		—		—
Total segment revenues	$	70	$	2,841	$	2,911


	Three Months Ended June 30, 2021
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	416	$	3,399	$	3,815
Intersegment revenues	87		—		87
Total segment revenues	$	503	$	3,399	$	3,902


	Six Months Ended June 30, 2022
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	154	$	8,270	$	8,424
Intersegment revenues	1,446		—		1,446
Total segment revenues	$	1,600	$	8,270	$	9,870


	Six Months Ended June 30, 2021
	Biopharmaceuticals		Exemplar		Total
Revenues from external customers	$	594	$	6,656	$	7,250
Intersegment revenues	328		—		328
Total segment revenues	$	922	$	6,656	$	7,578

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Segment Adjusted EBITDA for reportable segments	$	(10,454)	$	(10,651)	$	(18,516)	$	(17,699)

Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates	172		257		668		535
Add recognition of previously deferred revenue associated with upfront and milestone payments	—		379		1,446		686
Other expenses:
Interest expense	(2,063)		(4,633)		(4,101)		(9,137)
Depreciation and amortization	(1,835)		(2,071)		(3,753)		(4,145)
Gain on disposals of assets	—		7		—		7
Impairment losses	(638)		(543)		(1,120)		(543)

Stock-based compensation expense	(2,279)		(3,481)		(5,803)		(8,768)
Adjustment related to accrued bonuses paid in equity awards	—		—		1,698		—
Equity in net loss of affiliates	—		—		(1)		(3)
Other	(105)		(7)		(105)		(14)
Unallocated corporate costs	(8,914)		(10,052)		(18,974)		(18,246)
Eliminations	(32)		(204)		(1,543)		(575)
Consolidated net loss from continuing operations before income taxes	$	(26,148)	$	(30,999)	$	(50,104)	$	(57,902)

The table below reconciles total segment revenues from reportable segments to total consolidated revenues:


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Total segment revenues from reportable segments	$	2,911	$	3,902	$	9,870	$	7,578

Elimination of intersegment revenues	—		(87)		(1,446)		(328)
Total consolidated revenues	$	2,911	$	3,815	$	8,424	$	7,250